Therapeutic Immunity? Plasma, Immunoglobulin Therapies Shield CSL From Global Financial Crisis
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Australian-headquartered CSL Limited has not been affected by the global financial crisis CEO Brian McNamee told analysts Feb. 18 during a half-year earnings call. Australia's financial year begins July 1 and ends June 30
You may also be interested in...
First Out Of The Gate, CSL Begins Adult Trials Of H1N1 Flu Vaccine
PERTH, Australia - Melbourne-headquartered CSL Limited will begin clinical trials of its H1N1 influenza vaccine in healthy adults ages 18 to 64 July 22, and pediatric trials will commence Aug. 1, CSL said
First Out Of The Gate, CSL Begins Adult Trials Of H1N1 Flu Vaccine
PERTH, Australia - Melbourne-headquartered CSL Limited will begin clinical trials of its H1N1 influenza vaccine in healthy adults ages 18 to 64 July 22, and pediatric trials will commence Aug. 1, CSL said
U.S. FTC Blocks Australian CSL’s Acquisition of Talecris, Noting Consolidation Would Reduce Competition
PERTH, Australia - The U.S. Federal Trade Commission has authorized a lawsuit to stop Australian-based CSL Limited's $3.1 billion acquisition of Talecris Biotherapeutics, charging that the deal "would be illegal and would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies," the commission announced May 27